ArticleMediterranean journal of rheumatology2025
Secukinumab-Induced Severe Palmoplantar Psoriasis treated with Guselkumab: A Case Report.
Article in Mediterranean journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bimekizumab-induced paradoxical palmoplantar pustular psoriasis.JAAD case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Secukinumab is a monoclonal antibody targeting interleukin-17A (IL-17A), approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. While effective for many patients, it has been associated with paradoxical reactions such as exacerbation of psoriasis or drug-induced dermatitis. This case report presents a unique occurrence of severe palmoplantar psoriasis triggered by Secukinumab in a patient with psoriatic arthritis and multiple sclerosis (MS), necessitating a switch to another biologic therapy. Case Presentation: A 41-year-old female with a complex medical history including MS presented with severe desquamation and erythematous skin lesions on the hands, feet, and legs following treatment with secukinumab for psoriatic arthritis that necessitated discontinuation of secukinumab. A biopsy suggested drug eruption, with a differential diagnosis including palmoplantar pustular psoriasis. After multidisciplinary consultation, treatment was switched to guselkumab, an IL-23 inhibitor, which resulted in clinical improvement. Conclusion: This case highlights the potential for paradoxical reactions to IL-17 inhibitors and the efficacy of IL-23 inhibitors as an alternative therapy. Multidisciplinary approach was crucial for optimal patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.